

In re: Gallagher et al.  
Serial No.: 10/572,870  
Filed: May 9, 2007  
Page 2 of 2

### REMARKS

This response is supplemental to the response filed February 17, 2009, and is responsive to the telephonic request from Examiner Chandrakumar on March 10, 2009 that a list of claims corresponding to the elected restriction group be provided.

Applicants hereby reiterate their election of Group 1. This election is with traverse only to the extent that Applicants believe claim 83 should be grouped with Group 1 rather than with Groups 4-6. Claim 83 is directed to the pharmaceutical composition of claim 82 wherein the compound is present in an amount effective to inhibit the growth of multidrug resistant cells. As the composition of claim 83 does not comprise an additional active ingredient, it is more appropriately placed with claims 1-82 in Group 1.

Applicants state that claims 1-3, 5, 6, 11-13, 16-20, 22-25, 27-32, 35-47, 82, and 83 correspond to Group 1.

Applicants respectfully submit that this application is in condition for substantive examination, which action is respectfully requested. The Examiner is also encouraged to contact the undersigned directly at (919) 854-1400, if such contact will expedite the examination and allowance of the pending claims.

Respectfully submitted,



Robert A. Schwartzman, Ph.D.  
Registration No. 50,211

**USPTO Customer No. 20792**  
Myers Bigel Sibley & Sajovec  
Post Office Box 37428  
Raleigh, North Carolina 27627  
Telephone: 919/854-1400  
Facsimile: 919/854-1401

### CERTIFICATION OF TRANSMISSION

I hereby certify that this correspondence is being transmitted via the Office electronic filing system in accordance with § 1.6(a)(4) to the U.S. Patent and Trademark Office on March 12, 2009.

Signature: \_\_\_\_\_

Marthenn Salazar

#760619